CCND1 and cholesteatoma: The immunoblot (Figure 4(a)) showed that the GW0742 treatment increased the P-AKT (ser473) and its downstream effector Cyclin D1 and inhibited the level of PTEN, with altering phosphorylation activity of GSK3β in the cholesteatoma keratinocytes.